Stallergenes Greer provides Canadian physicians and their allergic patients with the sublingual grass pollen immunotherapy tablet ORALAIR®, the first and only sublingual immunotherapy tablet (SLIT) with a standardised 5-grass pollen composition.
Oralair® (sublingual tablet of grass pollen extract) is indicated for the treatment of symptoms of moderate to severe seasonal grass pollen allergic rhinitis with or without conjunctivitis in patients 5 to 50 years of age, confirmed by clinically relevant symptoms, a positive cutaneous test and a positive titre of the specific IgE to Poaceae grass pollen, who have suffered from allergic rhinitis with or without conjunctivitis for at least two pollen seasons and have not adequately responded to, or tolerated, conventional pharmacotherapy. Treatment with Oralair® should start about four months before the first appearance of grass pollen and continue until the end of the grass pollen season.
Our Dutton, Ontario facility also prepares named patient products for the Canadian market using licensed allergenic extracts manufactured in Lenoir, NC, USA. The company’s allergen extracts cover a vast array of allergens which can be tailored to the specific needs of patients in terms of composition, concentration and dosage. These personalised solutions, known as named patient products (NPPs), are prepared according to the allergist’s prescription and the patient profile using a stock solution obtained via the extraction of allergens (pollen, house dust mites, mould...). Each NPP has its own biological activity and is prepared for the unique needs of an individual patient.